LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 31

Search options

  1. Article ; Online: The Pediatric Endotracheal Aspirate Culture Survey (PETACS): Examining Practice Variation across Pediatric Microbiology Laboratories in the United States.

    Prinzi, Andrea M / Parker, Sarah K / Curtis, Donna J / Ziniel, Sonja I

    Journal of clinical microbiology

    2021  Volume 59, Issue 3

    Abstract: In the absence of evidence-based laboratory guidelines, the workup and interpretation of tracheal aspirate (TA) cultures remains controversial and confusing within the fields of clinical microbiology, infectious diseases, and critical care. Between 22 ... ...

    Abstract In the absence of evidence-based laboratory guidelines, the workup and interpretation of tracheal aspirate (TA) cultures remains controversial and confusing within the fields of clinical microbiology, infectious diseases, and critical care. Between 22 January and 24 February 2020, we conducted a national, web-based survey of microbiology laboratory personnel in free-standing pediatric hospitals and adult hospitals containing pediatric facilities regarding the laboratory practices used for TA specimens. We hypothesized there would be substantial center-level variability in laboratory processing of TA cultures. The response rate for the survey was 48% (73/153). There was a high level of variability in the criteria used for all processes, including specimen receipt, Gram staining, and culture reporting. Most respondents (77%) reported they do not reject TA specimens based on Gram stain criteria, and 44% of labs do not require that a minimum number of Gram stain fields be reviewed prior to reporting results. Overall, nonacademic hospital laboratories and pediatric-only laboratories are more likely to identify, report, and perform susceptibility testing on organisms from TA cultures, regardless of organism quantity or predominance. There is a substantial amount of process variability among pediatric microbiology laboratories that affects TA culture reporting, and which guides treatment decisions. This variation within and among labs makes clinical outcome studies related to TA cultures difficult to interpret. This study serves as a pragmatic step in informing the development of robust clinical guidelines. Clinical outcome and implementation studies are necessary to determine the effectiveness of guidelines for TA cultures.
    MeSH term(s) Adult ; Child ; Communicable Diseases ; Humans ; Laboratories ; Microbiology ; Staining and Labeling ; Surveys and Questionnaires ; United States
    Language English
    Publishing date 2021-02-18
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/JCM.02232-20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Savvy About SAVI.

    Liptzin, Deborah R / Cole, Lyndsey / Schulte, Greg / Curtis, Donna / Curran, Megan L / Alehashemi, Sara / Goldbach-Mansky, Raphaela / Galambos, Csaba / Deutsch, Gail / Weinman, Jason P

    American journal of respiratory and critical care medicine

    2024  

    Language English
    Publishing date 2024-04-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202309-1661IM
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: West Nile infections in pediatric solid organ transplant recipients.

    Levi, Marilyn E / Curtis, Donna J

    Pediatric transplantation

    2016  Volume 20, Issue 6, Page(s) 744–746

    MeSH term(s) Adolescent ; Child ; Child, Preschool ; Humans ; Immunocompromised Host ; Kidney Transplantation ; Male ; Pediatrics ; Postoperative Complications/diagnosis ; Postoperative Complications/immunology ; Postoperative Complications/therapy ; Prognosis ; West Nile Fever/diagnosis ; West Nile Fever/immunology ; West Nile Fever/therapy
    Language English
    Publishing date 2016-09
    Publishing country Denmark
    Document type Editorial
    ZDB-ID 1390284-2
    ISSN 1399-3046 ; 1397-3142
    ISSN (online) 1399-3046
    ISSN 1397-3142
    DOI 10.1111/petr.12710
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Impact of Organism Reporting from Endotracheal Aspirate Cultures on Antimicrobial Prescribing Practices in Mechanically Ventilated Pediatric Patients.

    Prinzi, Andrea M / Wattier, Rachel L / Curtis, Donna J / Ziniel, Sonja I / Fitzgerald, Allyson / Pearce, Kelly / Parker, Sarah K

    Journal of clinical microbiology

    2022  Volume 60, Issue 11, Page(s) e0093022

    Abstract: Endotracheal aspirate cultures (EACs) help diagnose lower respiratory tract infections in mechanically ventilated patients but are limited by contamination with normal microbiota and variation in laboratory reporting. Increased use of EACs is associated ... ...

    Abstract Endotracheal aspirate cultures (EACs) help diagnose lower respiratory tract infections in mechanically ventilated patients but are limited by contamination with normal microbiota and variation in laboratory reporting. Increased use of EACs is associated with increased antimicrobial prescribing, but the impact of microbiology reporting on prescribing practices is unclear. This study was a retrospective analysis of EACs from mechanically ventilated patients at Children's Hospital Colorado (CHCO) admitted between 1 January 2019 and 31 December 2019. Chart review was performed to collect all culture and Gram stain components, as well as antibiotic use directed to organisms in culture. Reporting concordance was determined for each organism using American Society for Microbiology guidelines. Days of therapy were calculated for overreported and guideline-concordant organisms. A multivariable model was used to assess the relationship between organism reporting and total days of therapy. Overall, 448 patients with 827 EACs were included in this study. Among patients with tracheostomy, 25 (8%) organisms reported from EACs were overreported and contributed 48 days of excess therapy, while 227 (29%) organisms from the EACs of endotracheally intubated patients were overreported, contributing 472 excess days of therapy. After adjustment, organism overreporting was associated with a >2-fold-higher rate of antimicrobial therapy than guideline-concordant reporting (incident rate ratio [IRR], 2.83; 95% confidence interval [CI], 1.23, 6.53; P < 0.05). Overreported organisms from respiratory cultures contribute to excess antimicrobial therapy exposure in mechanically ventilated patients. Microbiology laboratories have an opportunity to mitigate antimicrobial overuse through standardized reporting practices.
    MeSH term(s) Humans ; Child ; Retrospective Studies ; Respiration, Artificial ; Anti-Bacterial Agents/therapeutic use ; Respiratory Tract Infections/drug therapy
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2022-10-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/jcm.00930-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Under-immunization of pediatric transplant recipients: a call to action for the pediatric community.

    Feldman, Amy G / Curtis, Donna J / Moore, Susan L / Kempe, Allison

    Pediatric research

    2019  Volume 87, Issue 2, Page(s) 277–281

    Abstract: Vaccine-preventable infections (VPIs) are a common and serious complication following transplantation. One in six pediatric solid organ transplant recipients is hospitalized with a VPI in the first 5 years following transplant and these hospitalizations ... ...

    Abstract Vaccine-preventable infections (VPIs) are a common and serious complication following transplantation. One in six pediatric solid organ transplant recipients is hospitalized with a VPI in the first 5 years following transplant and these hospitalizations result in significant morbidity, mortality, graft injury, and cost. Immunizations are a minimally invasive, cost-effective approach to reducing the incidence of VPIs. Despite published recommendations for transplant candidates to receive all age-appropriate immunizations, under-immunization remains a significant problem, with the majority of transplant recipients not up-to-date on age-appropriate immunizations at the time of transplant. This is extremely concerning as the rate for non-medical vaccine exemptions in the United States (US) is increasing, decreasing the reliability of herd immunity to protect patients undergoing transplant from VPIs. There is an urgent need to better understand barriers to vaccinating this population of high-risk children and to develop effective interventions to overcome these barriers and improve immunization rates. Strengthened national policies requiring complete age-appropriate immunization for non-emergent transplant candidates, along with improved multi-disciplinary immunization practices and tools to facilitate and ensure complete immunization delivery to this high-risk population, are needed to ensure that we do everything possible to prevent infectious complications in pediatric transplant recipients.
    MeSH term(s) Age Factors ; Humans ; Immunocompromised Host ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Incidence ; Opportunistic Infections/epidemiology ; Opportunistic Infections/immunology ; Opportunistic Infections/prevention & control ; Organ Transplantation/adverse effects ; Organ Transplantation/trends ; Pediatrics/trends ; Risk Assessment ; Risk Factors ; Vaccination/trends ; Vaccine-Preventable Diseases/epidemiology ; Vaccine-Preventable Diseases/immunology ; Vaccine-Preventable Diseases/prevention & control
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2019-07-22
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 4411-8
    ISSN 1530-0447 ; 0031-3998
    ISSN (online) 1530-0447
    ISSN 0031-3998
    DOI 10.1038/s41390-019-0507-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A community divided: Post-transplant live vaccine practices among Society of Pediatric Liver Transplantation (SPLIT) centers.

    Kemme, Sarah / Sundaram, Shikha S / Curtis, Donna J / Lobritto, Steven / Mohammad, Saeed / Feldman, Amy G

    Pediatric transplantation

    2020  Volume 24, Issue 7, Page(s) e13804

    Abstract: Background: Historically, the IDSA and the AST have recommended that live vaccines not be administered post-transplant due to concern for induction of vaccine-strain disease in immunocompromised hosts. However, recent prospective studies and revised AST ...

    Abstract Background: Historically, the IDSA and the AST have recommended that live vaccines not be administered post-transplant due to concern for induction of vaccine-strain disease in immunocompromised hosts. However, recent prospective studies and revised AST guidelines published in April 2019 suggest that in the current era of immunosuppression minimization, live vaccines may be safely administered to select transplant recipients with resulting immunoprotection. The goal of this study was to assess current post-transplant live vaccine practices at individual pediatric liver transplant centers following the updated AST guidelines.
    Methods: A six-item email survey detailing center-specific post-transplant live vaccine practices followed by up to three response-specific questions were distributed between July 2019 and May 2020 to a representative from each center participating in the SPLIT consortium.
    Results: The overall survey response rate was 93% (41/44 centers). Only 29% (12/41) of centers offer live vaccines post-transplant; each of these 12 centers uses different eligibility criteria for live vaccines. There was no difference between large (ten or more transplants per year) and small (less than ten transplants per year) centers in likelihood to offer live vaccines post-transplant. The main reasons for a center not offering post-transplant live vaccines were safety concerns and inability to reach group consensus.
    Conclusions: The majority of pediatric liver transplant centers are reluctant to offer live vaccines post-transplant despite the updated AST guidelines. Prospective multicenter studies are needed to confirm safety and immunogenicity of live vaccines post-transplant.
    MeSH term(s) Child ; Follow-Up Studies ; Humans ; Liver Transplantation ; Postoperative Care/methods ; Primary Graft Dysfunction/prevention & control ; Retrospective Studies ; Societies, Medical ; Transplant Recipients ; United States ; Vaccination/statistics & numerical data ; Vaccines, Attenuated/administration & dosage
    Chemical Substances Vaccines, Attenuated
    Language English
    Publishing date 2020-08-26
    Publishing country Denmark
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1390284-2
    ISSN 1399-3046 ; 1397-3142
    ISSN (online) 1399-3046
    ISSN 1397-3142
    DOI 10.1111/petr.13804
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Use of Intravenous Posaconazole in Hematopoietic Stem Cell Transplant Patients.

    Strommen, Amanda / Hurst, Amanda L / Curtis, Donna / Abzug, Mark J

    Journal of pediatric hematology/oncology

    2018  Volume 40, Issue 4, Page(s) e203–e206

    Abstract: Background: Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal infections. There is no published data to inform prescribers on dosing of the intravenous (IV) formulation in the pediatric population. We ... ...

    Abstract Background: Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal infections. There is no published data to inform prescribers on dosing of the intravenous (IV) formulation in the pediatric population. We describe our experience including dosing, serum concentrations, and tolerability.
    Observations: Four patients (3 to 9 y) received IV posaconazole for treatment of documented/suspected invasive fungal infections. Patients achieved therapeutic concentrations on daily doses of 8.4 to 12.2 mg/kg and adverse effects were minimal.
    Conclusions: Higher dosing per body weight of IV posaconazole may be required in the pediatric population compared with adults to consistently achieve therapeutic concentrations.
    MeSH term(s) Administration, Intravenous ; Allografts ; Child ; Gastrointestinal Diseases/blood ; Gastrointestinal Diseases/drug therapy ; Gastrointestinal Diseases/etiology ; Graft vs Host Disease/blood ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Mucositis/blood ; Mucositis/drug therapy ; Mucositis/etiology ; Triazoles/administration & dosage ; Triazoles/pharmacokinetics
    Chemical Substances Triazoles ; posaconazole (6TK1G07BHZ)
    Language English
    Publishing date 2018-01-11
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1231152-2
    ISSN 1536-3678 ; 1077-4114 ; 0192-8562
    ISSN (online) 1536-3678
    ISSN 1077-4114 ; 0192-8562
    DOI 10.1097/MPH.0000000000001071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.

    Haynes, Andrew S / Curtis, Donna J / Campbell, Kristen / Giller, Roger H / Quinones, Ralph R / Verneris, Michael R / Abzug, Mark J

    Transplantation and cellular therapy

    2021  Volume 27, Issue 4, Page(s) 317–326

    Abstract: Following hematopoietic stem cell transplant (HSCT), patients are at increased risk of vaccine-preventable diseases (VPDs) and experience worse outcomes of VPDs compared to immunocompetent patients. Therefore, patients are routinely vaccinated post-HSCT ... ...

    Abstract Following hematopoietic stem cell transplant (HSCT), patients are at increased risk of vaccine-preventable diseases (VPDs) and experience worse outcomes of VPDs compared to immunocompetent patients. Therefore, patients are routinely vaccinated post-HSCT to restore VPD immunity. Published guidelines recommend revaccination based on time post-HSCT, although optimal revaccination timing and the value of using other clinical and laboratory variables to guide revaccination remain unclear. An institutional immune recovery-based protocol to guide timing of revaccination is used at Children's Hospital Colorado. This protocol incorporates time from transplant, time off immunosuppressive therapy and intravenous immunoglobulin replacement, absence of active graft-versus-host disease (GVHD), and minimum absolute CD4 count, absolute lymphocyte count (ALC), and immunoglobulin G (IgG) levels. The objective of this study is to evaluate the performance of this immune recovery-based revaccination protocol by determining rates of seroprotective vaccine responses achieved and describing demographic, clinical, and laboratory markers associated with protective antibody titers post-revaccination. Rates of seroprotection following revaccination were retrospectively determined for patients who received autologous or allogeneic HSCTs at Children's Hospital Colorado from 2007 to 2017. Percent seropositivity after revaccination was determined for ten VPDs: measles, mumps, rubella, varicella, tetanus, diphtheria, Haemophilus influenzae type B (Hib), poliovirus, hepatitis B virus (HBV), and Streptococcus pneumoniae. The impact of covariates, including post-HSCT vaccine timing, patient demographics, clinical features (diagnosis, donor and conditioning regimen data, GVHD, cytomegalovirus disease), and laboratory parameters (CD4 count, ALC, IgG level), on rates of seroprotection post-revaccination was determined using Wilcoxon rank sum, Fisher's exact, or chi-square tests, as appropriate. One hundred-twelve unique patients among 427 HSCT recipients had available data for both revaccination timing and vaccine titers. Among these, high rates of seroprotection were achieved after revaccination for rubella (100%), diphtheria (100%), tetanus (100%), and Hib (98%). More modest rates of seroprotection were achieved after revaccination with HBV (87%) and pneumococcal conjugate (85%) vaccines. Seroprotection was lower after revaccination with measles (76%), pneumococcal polysaccharide (72%), mumps (67%), and varicella (25%) vaccines. Greater rates of seroprotection were associated with younger age (hepatitis B vaccine, P = .04), lack of prior rituximab treatment (pneumococcal conjugate vaccine, P = .005), lack of total body irradiation (pneumococcal conjugate vaccine, P = .03), and receipt of a non-cord blood transplant (pneumococcal polysaccharide vaccine, P = .04). These results suggest that a revaccination protocol that incorporates both time post-HSCT and patient-specific indicators of immunologic recovery can achieve high rates of seroprotection against most VPDs. Seroprotection rates for HBV and PCV were notably among the highest reported in children post-HSCT, suggesting that an immune recovery-based protocol may improve seroprotection for some VPDs that frequently are associated with lower vaccine responses post-HSCT. Seroprotection rates for other VPDs remained suboptimal after revaccination. Therefore, evaluation of additional strategies, such as the use of novel markers of immune competence and new vaccines, to further optimize protection against VPDs in this population is warranted.
    MeSH term(s) Child ; Colorado ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunization, Secondary ; Pneumococcal Vaccines ; Retrospective Studies
    Chemical Substances Pneumococcal Vaccines
    Language English
    Publishing date 2021-01-28
    Document type Journal Article
    ZDB-ID 3062231-1
    ISSN 2666-6367
    ISSN (online) 2666-6367
    DOI 10.1016/j.jtct.2021.01.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs.

    Feldman, Amy G / Beaty, Brenda L / Curtis, Donna / Juarez-Colunga, Elizabeth / Kempe, Allison

    JAMA pediatrics

    2019  Volume 173, Issue 3, Page(s) 260–268

    Abstract: Importance: Pediatric transplant recipients are at risk for vaccine-preventable infections owing to immunosuppression, suboptimal response to vaccines before and after transplant, and potential underimmunization if transplant occurred early in life. ... ...

    Abstract Importance: Pediatric transplant recipients are at risk for vaccine-preventable infections owing to immunosuppression, suboptimal response to vaccines before and after transplant, and potential underimmunization if transplant occurred early in life. However, the incidence and burden of illness from vaccine-preventable infections in this population is unknown.
    Objectives: To evaluate in pediatric solid organ transplant recipients the number of hospitalizations for vaccine-preventable infections in the first 5 years after transplant and to determine the associated morbidity, mortality, and costs.
    Design, setting, and participants: A retrospective cohort study from January 1, 2004, to December 31, 2011, with 5 years of follow-up per participant (unless they died during the study period). The participants of this multicenter study through the Pediatric Health Information System were solid organ transplant recipients who were younger than 18 years at the time of transplant. Analysis began in July 2017.
    Exposures: Transplant.
    Main outcomes and measures: Hospitalizations for a vaccine-preventable infection during the first 5 years after transplant were ascertained using International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, clinical modification diagnosis codes. Data were collected on clinical care, outcomes, and costs during these hospitalizations.
    Results: Of 6980 transplant recipients identified, there were 3819 boys (54.7%), and the mean (SD) age at transplant was 8 (6.2) years. Overall, 1092 patients (15.6%) had a total of 1471 cases of vaccine-preventable infections. There were 187 of 1471 cases (12.7%) that occurred during transplant hospitalization. The case fatality rate was 1.7% for all infections. Excluding infections that occurred during transplant hospitalization (when all patients go to the intensive care unit), 213 of 1257 patients (17.0%) were hospitalized with a vaccine-preventable infection requiring intensive care. In multivariable analysis, age younger than 2 years at time of transplant and receipt of a lung, heart, intestine, or multivisceral organ were positively associated with increased risk of a hospitalization from a vaccine-preventable infection.Transplant hospitalizations complicated by vaccine-preventable infections were $120 498 more expensive (median cost) than transplant hospitalizations not complicated by vaccine-preventable infections.
    Conclusions and relevance: Hospitalization for vaccine-preventable infections occurred in more than 15% of solid organ transplant recipients in the first 5 years after transplant at a rate of up to 87 times higher than in the general population. There was significant morbidity, mortality, and costs from these infections, demonstrating the importance of immunizing all transplant candidates and recipients. Further research on improving immunization delivery, preventing nosocomial infections, and monitoring response to vaccines in the transplant population is needed.
    MeSH term(s) Child ; Child, Preschool ; Cost-Benefit Analysis ; Cross Infection/economics ; Cross Infection/epidemiology ; Cross Infection/prevention & control ; Female ; Hospital Costs ; Hospitalization/statistics & numerical data ; Humans ; Male ; Morbidity/trends ; Organ Transplantation/adverse effects ; Retrospective Studies ; Survival Rate/trends ; United States/epidemiology ; Vaccination/economics ; Vaccines/pharmacology
    Chemical Substances Vaccines
    Language English
    Publishing date 2019-01-11
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2701223-2
    ISSN 2168-6211 ; 2168-6203
    ISSN (online) 2168-6211
    ISSN 2168-6203
    DOI 10.1001/jamapediatrics.2018.4954
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Immunization Status at the Time of Liver Transplant in Children and Adolescents.

    Feldman, Amy G / Sundaram, Shikha S / Beaty, Brenda L / Torres, Richard / Curtis, Donna J / Kempe, Allison

    JAMA

    2019  Volume 322, Issue 18, Page(s) 1822–1824

    MeSH term(s) Adolescent ; Child ; Female ; Humans ; Liver Transplantation ; Male ; Vaccination/statistics & numerical data
    Language English
    Publishing date 2019-11-27
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2019.14386
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top